An observational study in Obesity, Chronic Pain and Abdominal Pain, sponsored by Medical University of Warsaw. Enrolling by invitation at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-31.
Sponsored by Medical University of Warsaw · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 162 studies in Obesity with a site in Poland — 46 open to participants now, 73 under way, 44 of them phase 3. Obesity · Poland.
Among the 162 studies in Obesity with a site in Poland, this one is the 10th largest by planned enrollment of the 26 observational ones that give a count, is one of 11 that started in 2024, is one of 26 observational ones, reaches primary completion later than 4 of the 72 other live ones, and was the 95th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →46 of the 162 studies in Obesity with a site in Poland are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Poland, United States, Belgium and 7 more countries
Ages 6–11
Ascletis Pharma (China) Co., Limited · Sites in Poland, United States, Canada and 4 more countries
Ages 18+
Ascletis Pharma (China) Co., Limited · Sites in Poland, United States, Czechia and 3 more countries
Ages 18+
AstraZeneca · Sites in Poland, United States, Argentina and 13 more countries
Ages 18+
AstraZeneca · Sites in Poland, United States, Argentina and 13 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
162 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 61 · Phase 4 9
First in 2001; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 334 across the 136 interventional studies, 183 across the 26 observational. Of the 71 that completed or were terminated, 14 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 162 have an industry lead sponsor. The 10 most frequent:
Medical University of Warsaw is the lead sponsor of 327 studies on the registry; 88 are open to participants now.
Medical University of Warsaw has 8 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
21 of the studies in Obesity with a site in Poland that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06662383Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
Add all 21 to your calendar (.ics) → With an account.
Among the 162 studies in Obesity with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to evaluate the prevalence of postoperative chronic pain, defined as the persistence of abdominal pain for more than 3 months after laparoscopic sleeve gastrectomy.
The main goal of this study is to determine the incidence of chronic abdominal pain among patients who have undergone laparoscopic sleeve gastrectomy. Patients who underwent this type of surgery at the Department of General Surgery and Transplantology of the Medical University of Warsaw between January 2020 and August 2024 will be qualified for the study. The participants will be asked to complete an online questionnaire, including a pain scale and PainDETECT Questionnaire.
Patients who underwent surgery at the Department of General Surgery and Transplantology of the Medical University of Warsaw between January 2020 and December 2024
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Questionnaire
Patients will receive a link to a web-based questionnaire on the prevalence and characteristics of pain symptoms including the PainDETECT questionnaire.
The presence of chronic abdominal pain after laparoscopic sleeve gastrectomy
The presence of pain after laparoscopic sleeve gastrectomy, which persists more than 3 months postoperatively.
Time frame: Baseline
PainDETECT Questionnaire score
PainDETECT is a simple, easy-to-use screening questionnaire. The questionnaire consists of 9 items and is completed by the patient. There are 7 weighted sensory descriptor items (never to very strongly) and 2 items relating to spatial and temporal pain characteristics. A total score of 19 or more is indicative of likely neuropathic pain.
Time frame: Baseline
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Apr 2025, 4 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Warsaw →